LCTX
Lineage Cell Therapeutics, Inc.
NYSE AmericanUSDEQUITY
DELAYED
Last price
1.08
■ 0.00 (0.00%)
MARKET · —
Price
Open
1.10
Prev close
1.08
Day high
1.11
Day low
1.07
Volume
709.51K
Market cap
—
P/E (TTM)
—
52W range
1.00 – 2.09
Trailing performance
Returnvs SPY
1W
+0.93%
+2.3%
1M
+0.93%
-2.8%
3M
-18.18%
-21.3%
6M
-40.33%
-51.4%
YTD
-35.33%
-47.6%
1Y
-9.24%
-29.2%
3Y
-22.30%
-96.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.09
-0.55% from price
SMA 20
1.09
-0.96% from price
SMA 50
1.18
-8.19% from price
SMA 100
1.30
-16.74% from price
SMA 200
1.50
-28.05% from price
EMA 12
1.09
-0.70% from price
EMA 26
1.11
-3.04% from price
EMA 50
1.17
-7.63% from price
RSI (14)
43.8
Neutral
MACD (12,26,9)
-0.03
Hist 0.00
ATR (14)
0.05
4.76% of price
Realised vol 30D
43.4%
Annualised
Bollinger upper
1.15
20, 2σ
Bollinger lower
1.03
20, 2σ
50 / 200 cross
Death
1.18 vs 1.50
Trend bias
Below 200
-28.05%
Risk profile
Beta vs SPY
1.44
More volatile than market
Correlation to SPY
0.33
Loosely linked
Realised vol 30D
43.4%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-47.4%
Peak to trough
Max drawdown 5Y
-86.0%
Peak to trough
ATR 14
0.05
4.76% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript
Motley Fool · 9d ago
Lineage Cell Therapeutics Q2 Earnings Call Highlights
MarketBeat · 13d ago
Lineage Cell Therapeutics, Inc. Q2 2026 Earnings Call Summary
Moby · 15d ago
Lineage Cell Therapeutics Inc (LCTX) (Q2 2026) Earnings Call Highlights: Cash Runway Extended, ...
GuruFocus.com · 16d ago
Lineage Cell (LCTX) Reports Q2 Loss, Lags Revenue Estimates
Zacks · 16d ago
Lineage Cell: Q2 Earnings Snapshot
Associated Press · 16d ago
Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Business Wire · 16d ago
Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
Business Wire · 23d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.